化放疗联合方案治疗原发性纵膈大B细胞淋巴瘤6例报告

薛梅; 朱玲; 刘静; 韩冬梅; 董磊; 王恒湘

doi:10.13201/j.issn.1004-2806.2014.01.014

化放疗联合方案治疗原发性纵膈大B细胞淋巴瘤6例报告

- 空军总医院血液科(北京, 100412)

详细信息

通讯作者: 王恒湘,E-mail:wanghengxiang123@aliyun.com

中图分类号: R733.4

收稿日期: 2013-06-01

Efficacy of chemoradiotherapy with rituximab in six patients with primary mediastinal large B-cell lymphoma

- Department of Hematology, General Hospital of Air Force, PLA, Beijing, 100412, China

More Information

Corresponding author: WANG Hengxiang, E-mail: wanghengxiang123@aliyun.com

Received Date: 01 June 2013

摘要

摘要: 目的:探讨原发性纵膈大B细胞淋巴瘤的临床特点、诊断、治疗和预后。方法:回顾性分析6例原发性纵膈大B细胞淋巴瘤的临床资料,均经活检获得病理诊断,并出现胸闷、气憋症状,均并发上腔静脉压迫综合征;心包受累6例,胸腔积液2例,肺部侵犯1例,骨骼侵犯1例。其中4例接受利妥昔单抗联合化放疗的方案治疗,2例进行单纯化放疗治疗。结果:完全缓解3例,部分缓解1例,进展死亡2例。结论:原发性纵膈大B细胞淋巴瘤有独特的临床和病理特点,早期较隐匿,缺乏特异性,随病情进展大多数患者逐渐出现胸闷、气憋症状,易并发上腔静脉压迫综合征。化疗联合放疗是其主要治疗措施,联合靶向药物治疗有助于提高疗效,预后多与疾病分期等有关。
- 纵膈大B细胞淋巴瘤 /
- 临床特征 /
- 放化疗 /
- 利妥昔单抗 /
- 预后
Abstract: Objective: To evaluate the clinical characteristics,diagnosis and prognosis of patients with primary mediastinal large B-cell lymphoma (PMBCL).Method: Clinical data of 6 patients with PMBCL were retrospectively analyzed.All the patients had superior vena cava syndrome and contiguous infiltration.Two received chemoradiotherapy alone and 4 received rituximab in combination with chemoradiotherapy.Result: Of the 6 patients,3 achieved complete remission,1 achieved partial remission and 2 had progressive disease and died.Conclusion: PMBCL is an aggressive diffuse large B-cell lymphoma entity with special clinical symptoms and morphoimmunological characteristics related to involvement of adjacent organs and tissues.Most of them have superior vena cava syndrome.Chemoradiotherapy remains to be the good treatment method.The combination of rituximab with chemoradiotherapy can lead to a remarkable progress.The prognosis of PMBCL is related to stage of the disease.
- mediastinal large B-cell lymphomal /
- clinical characteristics /
- chemoradiotherapy /
- rituximab /
- prognosis

HTML全文

参考文献(11)

[1]	STEIDL C,GASCOYNE R D.The molecular pathogenesis of primary mediastinal large B-cell lymphoma[J].Blood,2011,118:2659-2669.
[2]	JOHNSON P W,DAVIES A J.Primary mediastinal B-cell lymphoma[J].Hematology Am Soc Hematol Educ Program,2008,1:349-358.
[3]	BOLETI E,JOHNSON P W.Primary mediastinal B-cell lymphoma[J].Hematol Oncol,2007,25:157-163.
[4]	SAVAGE K J,AL-RAJHI N,VOSS N,et al.Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution:the British Columbia experience[J].Ann Oncol,2006,17:123-130.
[5]	AVILÉS A,NERI N,FERNÁNDEZ R,et al.Randomized clinical trial to assess the efficacy of radiotherapy in primary mediastinal large B-lymphoma[J].Int J Radiat Oncol Biol Phys,2012,83:1227-1231.
[6]	TAI W M,QUAH D,YAP S P,et al.Primary mediastinal large B-cell lymphoma:optimal therapy and prognostic factors in 41 consecutive Asian patients[J].Leuk Lymphoma,2011,52:604-612.
[7]	VASSILAKOPOULOS T P,PANGALIS G A,KAT-SIGIANNIS A,et al.Rituximab,cyclophosphamide,doxorubicin,vincristine,and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma:the emerging standard of care[J].Oncologist,2012,17:239-249.
[8]	ZHU Y J,HUANG J J,XIA Y,et al.Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients:clinical characteristics and prognostic factors[J].Int J Hematol,2011,94:178-184.
[9]	刘利,刘强,陈任安,等.自体外周血干细胞移植联合受累野放疗治疗纵隔巨块型淋巴瘤16例临床分析[J].内科急危重症杂志,2008,14(6):316-320.
[10]	NATH S V,SEYMOUR J F.Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma:role of rituximab,high-dose therapy,and allogeneic stem cell transplantation[J].Leuk Lymphoma,2005,46:1075-1079.
[11]	DE MELLO C A,DE ANDRADE V P,DE LIMA V C,et al.Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma[J].Leuk Lymphoma,2011,52:1495-1503.